Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy
Open Access
- 6 December 2024
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 53-56
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Standards for the care of people with cystic fibrosis (CF); Planning for a longer lifeJournal of Cystic Fibrosis, 2024
- Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular preventionEuropean Heart Journal, 2024
- Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortalityEuropean Heart Journal, 2023
- Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case seriesJournal of Cystic Fibrosis, 2022
- Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Cardiovascular complications in cystic fibrosis: A review of the literatureJournal of Cystic Fibrosis, 2022
- Serum leptin is associated with increased pulse pressure and the development of arterial stiffening in adult men: results of an eight-year follow-up studyHypertension Research, 2021
- Adiponectin, Leptin and Cardiovascular DisordersCirculation Research, 2021
- Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy peopleEuropean Heart Journal, 2020
- Absence of leptin signaling allows fat accretion in cystic fibrosis miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2018